SCHEMBL8949484

SCHEMBL8949484

N#Cc1cccc([C@@H](O)CBr)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.49
GRM4 Q14833 1/20 0.44
ENPP2 Q13822 1/20 0.43
TNF P01375 1/20 0.42
S1PR1 P21453 2/20 0.39
FAAH O00519 2/20 0.38
GLA P06280 1/20 0.38
MEP1A Q16819 1/20 0.38
MEP1B Q16820 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
GPR139 Q6DWJ6 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37
MMP12 P39900 1/20 0.37
MMP13 P45452 1/20 0.37
TSHR P16473 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
FBP1 P09467 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6540746 0.85 S1PR1 (0.45) GSK3BGRM4ENPP2TNFS1PR1
SCHEMBL6481575 0.85 S1PR1 (0.45) GSK3BGRM4ENPP2TNFS1PR1
SCHEMBL4697927 0.85 S1PR1 (0.45) GSK3BGRM4ENPP2TNFS1PR1
SCHEMBL9646909 0.84 LMNA (0.52) GSK3BGRM4ENPP2TNFS1PR1
SCHEMBL27948985 0.81 GSK3B (0.51) GSK3BGRM4ENPP2TNFS1PR1
SCHEMBL25933186 0.81 GLA (0.42) GSK3BGRM4ENPP2TNFS1PR1
SCHEMBL12056784 0.81 GRM4 (0.44) GSK3BGRM4ENPP2TNFS1PR1
SCHEMBL11601220 0.80 ENPP2 (0.48) GSK3BGRM4ENPP2TNFS1PR1
SCHEMBL4693798 0.80 ENPP2 (0.48) GSK3BGRM4ENPP2TNFS1PR1
SCHEMBL25263668 0.80 AOC3 (0.43) GSK3BGRM4ENPP2TNFS1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5561142-A Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity MERCK & CO., INC. (US) 1996-10-01 US disclosed
US-5541197-A Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity MERCK & CO., INC. (US) 1996-07-30 US disclosed